NYSE American - Delayed Quote USD

Can-Fite BioPharma Ltd. (CANF)

1.1100
-0.0050
(-0.45%)
At close: May 9 at 4:00:00 PM EDT
1.1086
-0.00
(-0.13%)
After hours: May 9 at 6:07:38 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CANF

Recent News: CANF

View More
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
GlobeNewswire 5 days ago
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
GlobeNewswire 23 days ago
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire 26 days ago
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
GlobeNewswire 26 days ago
Can-Fite Reports 2024 Financial Results and Clinical Update

Can-Fite Reports 2024 Financial Results and Clinical Update
GlobeNewswire 26 days ago

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESS Newswire last month
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
GlobeNewswire last month
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
GlobeNewswire last month
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
GlobeNewswire last month
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
GlobeNewswire last month
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
GlobeNewswire 2 months ago
View More

Related Tickers

ENLV Enlivex Therapeutics Ltd.
1.0200
-2.86%
 
PPBT Purple Biotech Ltd
2.2050
-0.68%
 
BLRX BioLineRx Ltd.
3.1700
-0.94%
 
PLUR Pluri Inc.
5.75
+8.29%
 
INAB IN8bio, Inc.
0.1574
-6.25%
 
IRD Opus Genetics, Inc.
0.9468
-4.92%
 
XTLB XTL Biopharmaceuticals Ltd.
1.2600
+1.61%
 
XFOR X4 Pharmaceuticals, Inc.
3.3700
+2.43%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.2534
-15.53%
 
CVM CEL-SCI Corporation
0.2468
-3.14%